Tagged with M

USA Rich Bendis, CEO and founder of BioHealth Innovation, discusses how the BioHealth Capital Region has grown into a leading US life sciences hub by connecting Maryland, Washington, D.C., and Northern Virginia through a regional, collaborative approach. From supporting early-stage companies with non-dilutive funding and strategic mentoring to helping international firms…

USA Susan Davenport, chief economic development officer at Opportunity Austin, outlines an ambitious vision for Central Texas as a rising force in the life sciences sector. Drawing on over 20 years of experience in regional economic development, Davenport highlights how Austin’s tech infrastructure, top-tier universities, and growing population position it as…

USA John Murphy, President and CEO of the Association for Accessible Medicines (AAM), outlines a compelling vision for improving access to high-quality, affordable medicines in the US. He stresses that by directing greater focus to the generic and biosimilar market, tackling structural challenges, safeguarding supply chains, and enabling strategic domestic investment,…

Denmark Michael Kocher, Chief Executive Officer of Xellia, brings over 15 years of pharmaceutical industry experience to his leadership role at the Danish API manufacturer. Under his leadership since October 2023, the company has undertaken a comprehensive strategic realignment, divesting its US operations while refocusing on its core competencies in fermentation-based…

USA Michael Hogue, CEO of the American Pharmacists Association (APhA), shares his vision for the future of the pharmacy profession and its evolving role in healthcare. He discusses the strategic priorities for pharmacists in the coming years, emphasizing the need to reshape public perception, expand the role of pharmacists in disease…

USA Kendalle O’Connell, President and CEO of MassBio, shares how Massachusetts has built one of the world’s most dynamic life sciences hubs through a mix of bold public investment, targeted programmes, and a “big tent” approach to collaboration. From guiding companies into the right communities with the BioReady programme to fostering…

China A roundup of some ot the biggest stories coming out of China’s biopharma industry: Chinese pharma shifts to local reagent suppliers; WuXi Biologics launches new stable cell line platform; Fosun and Expedition Therapeutics ink respiratory licensing deal, and GSK lands USD 500 million 12-drug agreement with Hengrui Pharma.   China…

Switzerland 2024 marked a transformative year for Switzerland’s regulatory authority, Swissmedic. As part of its ambitious 2023–2026 strategy, the agency made significant strides towards digital transformation and improving access to innovative medicines while delivering a notable 12 percent increase in new drug approvals with 46 new active substances. Drive for Digital…

USA The latest stories from healthcare and the life sciences in the US. Vinay Prasad is reinstated as head of the FDA’s CBER following a brief resignation; HHS fires Gray Delany amid fallout from abrupt mRNA contract cuts; the federal Task Force on Safer Childhood Vaccines is revived after three decades…

Switzerland As kidney disease places mounting pressure on global healthcare systems, innovation in dialysis becomes all the more critical, especially for patients receiving therapy at home. Enter Vivatum: a Swiss-Swedish medtech venture co-founded by industry expert Daniel Maechler, dedicated to reimagining Continuous Ambulatory Peritoneal Dialysis (CAPD) through digital precision, intuitive design,…

Switzerland FarmaMondo’s evolution over the past eight years is a compelling case study in what it takes to bring life-saving innovation to the world’s most overlooked patients, not through philanthropy but through a commercially sustainable, ethically grounded model. Operating from a Swiss base with deep roots in legal rigour and regulatory…

Switzerland Jorge Santos da Silva is the CEO and Co-founder of MoonLake Immunotherapeutics, a Swiss biotech company known for its bold approach to drug development. With a background in neuroscience, a decade in academic research, and over 15 years at McKinsey, where he was a Senior Partner, advising pharma and biotech…